Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MEK162 in Hepatic Impairment
NCT02050815Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Mar 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of binimetinib in melanoma and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Pfizer. Primary endpoints: Time to Maximum Plasma Concentration at 120 hours, Maximum Plasma Concentration at 120 hours and 2 more. Started Mar 2014; status: terminated.
02
Drugs
binimetinib
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02050815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02050815.